CTK Biotech specializes in the development of rapid diagnostic tests that facilitate the non-invasive detection of various infectious diseases. Their product lineup includes the OnSite H. pylori Ab Combo Rapid Test, which allows for the simultaneous detection of antibodies related to Helicobacter pylori without requiring patient preparation, thereby reducing discomfort during diagnosis. Additionally, the OnSite Duo Dengue Ag-IgG/IgM Rapid Test can detect Dengue IgG/IgM antibodies and NS1 antigen in under 25 minutes, while the OnSite Influenza A/B Ag Rapid Test provides reliable results for influenza detection in just 15 minutes. These tests are designed for use by minimally skilled personnel and do not require laboratory equipment, making them accessible for various healthcare settings.

CTK Biotech's products are validated against CDC-recommended strains, ensuring high accuracy and reliability. For instance, the OnSite Influenza A/B Ag Rapid Test demonstrates impressive clinical performance, with a relative sensitivity of 99.34% for Influenza A and 100% for Influenza B, alongside a specificity of 100% for both. The company also offers a range of other diagnostic tests, including those for COVID-19 and respiratory syncytial virus (RSV), further expanding their portfolio in infectious disease diagnostics. Their commitment to providing rapid and accurate diagnostic solutions has made them a trusted partner for clinicians worldwide.

United States

CTK Biotech is a biotechnology company that specializes in medical diagnostics for healthcare applications.

CTK Biotech

Company Details